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Abstract
Background
Selenium and coenzyme Q10 are important antioxidants in the body. As the intake of sele-
nium is low in Europe, and the endogenous production of coenzyme Q10 decreases as age
increases, an intervention trial using selenium and coenzyme Q10 for four years was per-
formed. As previously reported, the intervention was accompanied by reduced cardiovascu-
lar mortality. The objective of the present study was to analyze cardiovascular mortality for
up to 10 years after intervention, to evaluate if mortality differed in subgroups differentiated
by gender, diabetes, ischemic heart disease (IHD), and functional class.
Methods
Four-hundred forty-three healthy elderly individuals were included from a rural municipality
in Sweden. All cardiovascular mortality was registered, and no participant was lost to the fol-
low-up. Based on death certificates and autopsy results mortality was registered.
Findings
Significantly reduced cardiovascular mortality could be seen in those on selenium and
coenzyme Q10 intervention. A multivariate Cox regression analysis demonstrated a
reduced cardiovascular mortality risk in the active treatment group (HR: 0.51; 95%CI 0.36–
0.74; P = 0.0003). The reduced mortality could be seen to persist during the 10-year period.
Subgroup analysis showed positive effects in both genders. An equally positive risk
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reduction could be seen in those with ischemic heart disease (HR: 0.51; 95%CI 0.27–0.97;
P = 0.04), but also in the different functional classes.
Conclusions
In a 10-year follow-up of a group of healthy elderly participants given four years of interven-
tion with selenium and coenzyme Q10, significantly reduced cardiovascular mortality was
observed. The protective action was not confined to the intervention period, but persisted
during the follow-up period. The mechanism explaining the persistency remains to be eluci-
dated. Since this was a small study, the observations should be regarded as hypothesis-
generating.
Introduction
The trace element selenium is essential for all living cells[1, 2]. It is mostly found as selenopro-
teins in the body, including glutathione peroxidases, thioredoxin reductase and selenoprotein
P, which protect against oxidative stress. Increased vascular oxidative stress and endothelial
dysfunction in patients with coronary heart disease have been reported[3, 4]. However, the
association between ischemic heart disease and suboptimal selenium intake has been a contro-
versial topic and there are conflicting results regarding the effectiveness of selenium interven-
tion in patients with ischemic heart disease[5–8]. As the selenium content in the soil is low in
Europe compared to the US, supplementation or biofortification has been regarded as logical
in European regions[9, 10]. The mean intake of selenium in Europe is estimated to be about
40 μg/day, whereas the estimated mean intake in the US is 134 μg/day in males and 93 μg/day
in females. These inter-continental differences in selenium intake provide an explanation for
inconsistent results of selenium supplementation that are reported in one Cochrane review
[11]. However, there are some reports from small study samples in Europe indicating a higher
mortality in those with low selenium intake[12–14]. Our research group have recently reported
higher cardiovascular mortality in a community population with low plasma selenium concen-
tration[15].
Xia et al. demonstrated an interrelationship between selenium and coenzyme Q10 (ubiqui-
none) in the metabolic pathway to the active form of coenzyme Q10 (ubiquinol). Moreover, an
adequate presence of coenzyme Q10 is needed for optimal synthesis of selenocysteine-contain-
ing enzymes[16]. Similarly, a deficiency of selenium could influence the ability to get adequate
concentrations of active coenzyme Q10 in cellular compartments. Coenzyme Q10 has been
shown to have effects on the endothelial function[17]. It is also known that coenzyme Q10 is a
powerful anti-oxidant, mainly against lipid peroxidation[18]. Reports have shown that ubqui-
none also reduces inflammatory response [19] in those with diabetes [20]. It is reported that
the endogenous production of coenzyme Q10 decreases after the age of 20, and the myocardial
production is reduced to half at the age of 80 [21]. Thus, elderly people living in geographical
areas with low selenium content in the soil and in their food may be at increased risk of heart
disease and premature death.
A dietary supplementation trial with both selenium and coenzyme Q10 to 443 elderly Swed-
ish community members was performed during 2003 until 2010. The main results have previ-
ously been published[22]. The intervention time was four years, and the median follow-up
time was 5.2 years. The main results were significantly reduced cardiovascular mortality,
improved cardiac function as evaluated on echocardiography, and a reduced increase of the N-
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terminal fragment of proBNP (NT-proBNP), a cardiac peptide biomarker. Recently, we also
have reported increased health-related quality of life in those with active treatment, but also
data showing more days out of hospital in this elderly population (in press). However, less is
known about possible long-term effects of the supplementation in the post-intervention period.
Also, it would be of interest to separately evaluate specific sub-groups such as participants with
diabetes, those with a history of IHD, and those in different functional classes, to see if specific
sub-groups benefit more or less from this intervention.
The primary aim of the present study was to evaluate the cardiovascular effects of the inter-
vention in the population under study 10 years after the introduction of a four-year period of
supplementation. A secondary aim was to establish if there were different effects on CV-moral-
ity in gender, diabetes, IHD and functional classes as measured by New York Heart Association
functional Class (NYHA class).
Materials and Methods
The design of the main study has been published elsewhere[22]. In brief, 443 elderly healthy
participants were given dietary supplementation of 200 mg/day of coenzyme Q10 capsules
(Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 μg/day of organic sele-
nium yeast tablets (SelenoPrecise 200 μg, Pharma Nord, Vejle, Denmark), or a similar placebo.
The study supplementation was taken in addition to regular medication. All study medication
(active drug and placebo) not consumed were returned and counted. All participants were
examined by one of three experienced cardiologists. A new clinical history was recorded, and a
clinical examination was performed, including blood pressure, assessment of New York Heart
Association functional class (NYHA class) as well as ECG and echocardiography. Doppler
echocardiographical examinations were performed with the participant in the left lateral posi-
tion. The ejection fraction (EF) readings were categorized into four classes with interclass limits
placed at 30%, 40% and 50% [23, 24]. Normal systolic function was defined as EF 50%, while
severely impaired systolic function was defined as EF< 30%.
As the intervention time was unusually long, 48 months, only 228 participants completed
the study, 86 died during the total intervention time, and 129 (29.1%) decided not to complete
the study. The reasons for the latter have been presented in detail in the main publication, but
the main reason was too many tablets to take [22]. Written, informed consent was obtained
from all patients. The study was approved by the Regional Ethical Committee in Linköping,
Sweden, and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. This study
was registered at Clinicaltrials.gov, and has the identifier NCT01443780
Biochemical analyses
All blood samples were obtained while the patients were at rest in a supine position. The blood
samples were collected in plastic vials containing EDTA (ethylenediamine tetracetic acid). The
vials were placed on ice before chilled centrifugation at 3000g, and then frozen at -70°C. No
sample was thawed more than twice. NT-proBNP 1–76 was measured on the Elecsys 2010 plat-
form (Roche Diagnostics, Mannheim, Germany). The total coefficient of variation was 4.8% at
26 pmol/L and 2.1% at 503 pmol/L (n = 70).
Mortality
All instances of cardiovascular mortality (CV mortality) were registered. The mortality infor-
mation was obtained from the National Board of Health and Welfare in Sweden, which regis-
ters all deaths of Swedish citizens based on death certificates or autopsy reports. Written,
informed consent was obtained from all patients.
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Statistical methods
Descriptive data are presented as percentages or mean ± SD. A Student’s unpaired two-sided
T-test was used for continuous variables and the Chi-square test was used for discrete variables.
Kaplan-Meier analysis was used to demonstrate CV mortality during the follow-up period.
Cox proportional hazard regression analysis was used to evaluate risk of cardiovascular mortal-
ity. The independent variables included in the multivariate model were variables known to be
associated with CV-mortality: age, smoking, hypertension, diabetes, ischemic heart disease,
New York Heart Association functional (NYHA) class III, Hb<120g/L, EF<40% and 4th quar-
tile of NT-proBNP.
A P-value of<0.05 was considered statistically significant. All data were analyzed using
standard software (Statistica v. 12.5, Statsoft Inc, Tulsa, OK).
Results
The study population were followed regarding CV mortality during a median follow-up time
of 3668 days (range 348–4488), thus 10 years. In the survivor group the median follow-up time
was 3836 days (range 689–4488), and in the non-survivor group a median follow-up time of
2505 days (range 348–4347) was recorded.
From the basal characteristics it could be seen that the two populations were balanced at the
start of the intervention in all but one variable, use of ACE-inhibitors (15.8% vs 24.3%;
P = 0.03)(Table 1).
At the start of the intervention the two groups were the same age (78 years), the relation
between males/ females was well balanced, and the proportion of smokers was equal between
the two groups (9%). Of the total population, 21% had diabetes, which was the same in the two
groups, and the proportions with hypertension were equally well balanced (71.5% vs. 75.7%).
The proportions suffering from IHD were equal in the two groups (21.3% vs. 23.9%). The clini-
cal characteristics of the two groups active treatment and placebo are also demonstrated at end
of the intervention, and after 10 years of follow-up (Table 1). It could be seen that the part of
participants classified to NYHA class III, that is those with a marked limitation of physical
activity, is more reduced in the placebo group after 10 years, compared to start of intervention,
or at the stop of the intervention, and compared to the active treatment group. The same trend
could be seen regarding the part with at least moderately reduced systolic cardiac function
(EF<40%) in the placebo group (Table 1).
Cardiovascular mortality within 10 years
Evaluating the mortality using a follow-up time of 10 years revealed a lower CV mortality in
the active treatment group compared to the placebo group (46/221 vs. 86/222; χ2:17.01; P =
<0.0001). The CV mortality during the follow-up period is demonstrated in a Kaplan-Meier
graph, where the two groups are indicated (Fig 1).
Evaluating risk, the active treatment group displayed significantly reduced cardiovascular
risk compared to the placebo group in the univariate Cox regression analysis (HR: 0.52; 95%CI
0.36–0.74; P = 0.0004). If applying a multivariate model including well-known variables influ-
encing cardiovascular risk, and the well-known biomarker NT-proBNP to the model, a signifi-
cant risk reduction could be displayed by the active supplementation of selenium and
coenzyme Q10 (HR: 0.51; 95%CI 0.36–0.74; P = 0.0003) (Table 2).
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Subgroup analyses
Dividing the study population into the two genders revealed significantly reduced cardiovascu-
lar mortality in both genders (males active treatment 34/115 vs. 49/110; χ2:5.42; P = 0.02;
females active treatment 12/106 vs. 37/112; χ2:8.31; P = 0.004).
Evaluating those with a history of diabetes showed a reduced CV mortality for those on
active treatment (14/47 vs. 26/48; χ2:5.79; P = 0.0016). Applying these data into a univariate
Cox proportional hazard regression analysis showed reduced cardiovascular risk for those on
active treatment (HR: 0:51; 05%CI 0.27–0.98;P = 0.04).
Analyzing those with a history of IHD, a trend towards less CV mortality could be seen in
those on active treatment (19/47 vs. 31/53; χ2: 3.25; P = 0.071). The CV mortality over time is
demonstrated in a Kaplan-Meier graph (Fig 2).
However, applying this small study sample into a multivariate model revealed a significantly
reduced risk of CV mortality for those on active treatment (HR: 0.51; 95%CI 0.27–0.97;
P = 0.04) (Table 3).
Finally, by evaluating participants with different functional class according to the NYHA
classification, it could be demonstrated that irrespective of the functional class, those on active
treatment had less CV mortality (NYHA I: active treatment: 19/119 vs. placebo: 26/111; χ2:
3.83; P = 0.05; NYHA II: active treatment: 14/61 vs. placebo: 26/64; χ2: 4.48; P = 0.03; NYHA
III; active treatment: 16/41 vs. placebo: 34/47; χ2: 9.91; P = 0.002). The distribution of CV mor-
tality over time in the different NYHA classes is presented in Figs 3–5.
Table 1. Population characteristics at inclusion, at end of the intervention, and after 10 years.
At study start At the end of intervention After 10 years
Active p-value Placebo Active p-value Placebo Active p-value Placebo
n 221 222 208 194 175 136
Age, mean 78 78 82 82 88 88
Males/Females, n 115/106 110/112 105/103 90/104 81/94 61/75
Smokers, n (%) 21 (9.5) 0.86 20 (9.0) 17 (8.2) 0.98 16 (8.2) 10 (5.7) 0.74 9 (6.6)
Diabetes, n (%) 47 (21.3) 0.93 48 (21.6) 44 (21.2) 0.99 41 (21.1) 33 (18.9) 0.54 22 (16.2)
Hypertension, n (%) 158 (71.5) 0.32 168 (75.7) 148 (71.2) 0.30 147 (75.8) 123 (70.3) 0.44 101 (74.3)
IHD, n (%) 47 (21.3) 0.51 53 (23.9) 44 (21.2) 0.81 43 (22.2) 28 (16.0) 0.97 22 (16.2)
NYHA class I, n (%) 118 (53.4) 0.32 108 (48.6) 115 (55.3) 0.34 98 (50.5) 103 (58.9) 0.70 83 (61.0)
NYHA class II, n (%) 61 (27.6) 0.77 64 (28.8) 56 (26.9) 0.58 57 (29.4) 47 (26.9) 0.83 38 (27.9)
NYHA class III, n (%) 41 (18.6) 0.49 47 (21.2) 36 (17.3) 0.74 36 (18.6) 25 (14.3) 0.21 13 (9.6)
NYHA class IV, n (%) 0 0 0 0 0 0
Unclassiﬁed, n 1 3 1 3 0 2
Medical Treatment
ACEI, n (%) 35 (15.8) 0.03 54 (24.3) 33 (15.9) 0.04 47 (24.2) 23 (13.1) 0.11 27 (19.9)
Beta blockers, n (%) 81 (36.7) 0.40 73 (32.9) 76 (36.5) 0.46 64 (33.0) 62 (35.4) 0.26 40 (29.4)
Digitalis, n (%) 11 (5.0) 0.99 11 (5.0) 10 (4.8) 0.94 9 (4.6) 7 (4.0) 0.86 6 (4.4)
Diuretics, n (%) 70 (31.7) 0.08 88 (39.6) 64 (30.8) 0.06 77 (39.7) 52 (29.7) 0.52 45 (33.1)
Statins, n (%) 45 (20.7) 0.50 51 (23.0) 42 (20.2) 0.46 45 (23.2) 36 (20.6) 0.87 29 (21.3)
Examinations
Hb<120g/L, n (%) 23 (10.4) 0.39 29 (13.1) 21 (10.1) 0.47 24 (12.4) 17 (9.7) 0.96 13 (9.6)
EF<40%, n (%) 16 (7.2) 0.87 17 (7.7) 15 (7.2) 0.68 12 (6.2) 10 (5.7) 0.41 5 (3.7)
Note: ACEI: ACE- inhibitors; EF: Ejection fraction according to echocardiography; IHD: Ischemic heart disease; NYHA: New York Heart Association
functional class
doi:10.1371/journal.pone.0141641.t001
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Other mortality within 10 years
A reduced all-cause mortality in the active group compared to the placebo group (98/221 vs.
120/222; χ2:4.18; P = 0.041) could also be seen. Evaluating mortality in malignancies was
Fig 1. Kaplan-Meier graph illustrating cardiovascular mortality in the study population in those supplemented with selenium and coenzymeQ10
versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.
doi:10.1371/journal.pone.0141641.g001
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performed, with no differences between the two groups (active treatment: 20/221 vs. placebo
19/222; χ2:0.03; P = 0.86).
Discussion
The results presented in this study are from a 10-year follow-up of a project in which selenium
and coenzyme Q10 were given as a combined dietary supplement to 443 elderly community
inhabitants. The present data indicate a post intervention persistency of the protection against
CV mortality. The mortality rate at 5.2 years of follow-up, and at 10 years of follow-up are pre-
sented in Table 4. In the table the figures from official Swedish mortality statistics are also
added in comparison. However, as the sample size of the present study is limited, the figures
should be interpreted with caution.
Surprisingly, the 48-month intervention appears to be accompanied by durable cardiovascu-
lar protection after termination of the supplements. From the analyses of subgroups it could be
verified that patients with IHD, and/ or diabetes had an increased cardiovascular risk, but they
appeared to be equally protected by the active combined supplementation treatment. And irre-
spective of the functional class of the participants, positive effects of the intervention could be
seen. However, as the subgroups were small, the overall interpretation of our results is difficult.
Positive effects could be observed in males as well as in females, although a trend towards a
better protective effect in females might be suggested. A recent German study of healthy elderly
also suggested gender differences [25] as it reported lower levels of coenzyme Q10 and ubiqui-
nol in females.
Increased oxidative stress[26–28], and inflammatory response[29–31], which may contrib-
ute to the progression of atherosclerosis, have been reported in elderly people.
It is well known that both selenium and coenzyme Q10 are needed for defense mechanisms
against oxidative stress, a condition that may accompany any inflammation, and thus continu-
ously affect any human cell throughout its lifetime. Endothelial cells and platelets in elderly
people may be particularly exposed as they surround the continuous oxygen transport in the
circulation, accompanied by increasing inflammatory response with age [32, 33]. It has been
shown that increased oxidative stress is associated with impaired cardiac ventricular function.
This can occur in the absence of myocardial infarction [34], although it is more obvious after
Table 2. Cox proportional hazard regression analysis evaluating risk of cardiovascular mortality by
supplementation of selenium and coenzymeQ10 combined in a multivariate model after 10 years of
follow-up after 4 years of intervention to an elderly community population.
Variables Hazard ratio 95%CI P-value
Age 1.12 1.06–1.18 <0.0001
Smoking 2.04 1.26–3.29 0.004
Hypertension 1.32 0.87–2.01 0.19
Diabetes 1.59 1.09–2.32 0.02
IHD 1.38 0.92–2.06 0.12
NYHA class 3 2.05 1.38–3.06 0.0004
Hb<120g/L 0.95 0.59–1.52 0.82
EF<40% 0.75 0.42–1.33 0.33
NT-proBNP Q4 2.26 1.52–3.38 <0.0001
Active treatment 0.51 0.36–0.74 0.0003
Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proBNP;
NYHA: New York Heart Association functional class; Q4: 4th quartile
doi:10.1371/journal.pone.0141641.t002
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an infarction[35]. Selenium, through selenium-containing enzymes, is a strong antioxidant,
and optimal levels are needed for the maintenance of normal cell function. Ubiquinone is also
essential for optimal antioxidant function. Positive effects of supplementation of coenzyme
Q10 on endothelial function have also been reported in the literature [36].
Fig 2. Kaplan-Meier graph illustrating cardiovascular mortality in the study population with ischemic heart disease, in those supplemented with
selenium and coenzymeQ10 versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.
doi:10.1371/journal.pone.0141641.g002
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An important question of the present evaluation was related to the possible persistency of
the effect of supplementation on cardiovascular mortality after termination of the supplemen-
tation. From Table 1 it could be noted that from the variables EF<40%, and NYHA class III,
thus those most diseased from a cardiovascular perspective, a more pronounced reduction of
the amount of participants still alive could be seen in the placebo group between end of inter-
vention and at the12 years of follow-up, compared to the active treatment group. This might
indicate that the part most diseased died to a greater extent in the placebo group compared to
the active treatment group also during the time after the termination of the intervention. An
explanation might be a decrease of the progression of the cardiovascular disease during the
intervention as could be seen from increased inflammatory activity that is reduced by the inter-
vention [37] and where at the end result, if not given intervention, increased atherosclerosis
and macroscopic cardiovascular injuries as a result could be registered up to 6 years after the
termination of the intervention.
As the intervention was unusually long—four years—the effect of supplementation of sele-
nium and coenzyme Q10 in this population, with obvious suboptimal plasma levels of sele-
nium, is probably more profound than in individuals with marginally lowered selenium. The
mean plasma selenium in the present population was about 67 μg/L [15], whereas optimization
of the extracellular selenoprotein P requires plasma levels of 120 μg/L [38]. Here, it is relevant
that selenium-containing enzymes operate not only as anti-oxidants, but also as anti-inflam-
matory and anti-atherothrombotic agents [39–41]. Thus, Helmersson et al. in a 27-year follow-
up of Swedish males with a mean selenium concentration of 77 μg/L [42, 43] showed that high
selenium concentration predicted lower signs of oxidative stress and reduced signs of inflam-
mation, as seen inter alia from PGF2α. It should be noted that Swedish selenium levels are
much lower than those reported from US populations [43]. The elderly are also more likely to
have low levels of coenzyme Q10. Furthermore, a complex relationship between coenzyme
Q10 and selenium exists, in which selenium is needed in order to facilitate reduction of coen-
zyme Q10 to ubiquinol, the active form. [16, 44]. A hypothesis that can be proposed from our
results is that the intervention with selenium combined with coenzyme Q10 inhibits the patho-
genesis of irreversible, presumably structural, changes preceding cardiovascular events.
However, part of the results could also be explained by the fact that the community under
study developed an increased interest in supplementation with selenium and coenzyme Q10,
Table 3. Cox proportional hazard regression analysis evaluating risk of cardiovascular mortality by
supplementation of selenium and coenzymeQ10 combined in a multivariate model after 10 years of
follow-up after 4 years of intervention to an elderly with ischemic heart disease from a community.
Variables Hazard ratio 95%CI P-value
Age 1.15 1.05–1.26 0.004
Smoking 2.50 1.10–5.70 0.03
Hypertension 1.79 0.84–3.82 0.13
Diabetes 1.77 0.93–3.36 0.08
NYHA class 3 1.73 0.89–3.34 0.10
Hb<120g/L 0.96 0.46–2.00 0.92
EF<40% 0.92 0.44–1.93 0.82
NT-proBNP Q4 0.72 0.36–1.42 0.34
Active treatment 0.51 0.27–0.97 0.04
Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proBNP;
NYHA: New York Heart Association functional class; Q4: 4th quartile
doi:10.1371/journal.pone.0141641.t003
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as previously mentioned, and continued the supplementation. However, if this were so, indi-
viduals randomized to placebo might also have started supplementation on their own.
Increased or decreased risk of malignancies has been discussed in the literature as a result of
supplementation with selenium. In this report, no sign of increased or decreased malignancies
Fig 3. Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA functional class I, in those supplemented with
selenium and coenzymeQ10 versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.
doi:10.1371/journal.pone.0141641.g003
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could be seen in the intervention group. However, it should be admitted that the study sample
was small, and not intended for detection of such associations.
That supplementation with antioxidants could have positive effects also after the interven-
tion has terminated has been reported by Bonelli et al. [45]. They evaluated patients with
Fig 4. Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA functional class II, in those supplemented with
selenium and coenzymeQ10 versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.
doi:10.1371/journal.pone.0141641.g004
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recurrent adenomas and where a supplementation of vitamin A, C and E combined with
200microgram selenium was given during 5 years. In a 15 years cumulative follow-up they
could present data indicating a persisting effect of the reduction on recurrences of adenomas in
the active intervention group. The study is small with several limitations. However, taken
Fig 5. Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA functional class III, in those supplemented with
selenium and coenzymeQ10 versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.
doi:10.1371/journal.pone.0141641.g005
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together with the results presented in the present study this could support the explanation that
an anti-oxidative effect during the intervention might influence the macroscopic consequences
of the disease evaluated.
Limitations
The sample size of this intervention is an important limitation, and this makes the evaluation
difficult, and a greater sample would certainly have been better. However, as the baseline levels
of both selenium and coenzyme Q10 were measured, and documented as low, the need for sup-
plementation was documented. The choice of outcome variable was chosen as a defined and
documented outcome variable, even if uncertainties also exist in death certificates.
As evaluations of different subgroups were performed, the small sample sizes become even
more obvious, and the results should be interpreted with caution. However, we consider that
the presented data, irrespective of interpretations, should be regarded as hypothesis-
generating.
The limited age span also represents a limitation, making extrapolation of the results diffi-
cult. However, in an elderly population the incidence of comorbidities is higher compared to
younger persons, and an effect on cardiovascular disease competes with other disease states,
making the results even more intriguing.
No measurements of the serum levels of selenium, or coenzyme Q10 have been done during
the follow-up period. However, as earlier stated, the probability is high that those who started
supplementation on their own are equally distributed between the two groups. Secondly, the
effect of those taking selenium and coenzyme Q10 during the follow-up period will result in
diminishing the difference between the two evaluated groups, why an underestimation of the
actual effect could be the result.
Finally the population was a homogenous white group, living in Sweden, making extrapola-
tion of results to other groups with other selenium concentrations difficult.
Conclusion
A 10-year evaluation of CV mortality in an elderly Swedish healthy population that was given
dietary supplementation with selenium and coenzyme Q10 over a period of four years, indi-
cated a reduced risk of cardiovascular mortality by 50% and a post-intervention persistency of
protection against CV mortality. The result could also be seen in the different genders, in those
with diabetes, and in those with IHD. However, the mechanism explaining the persistent effect
remains to be elucidated. Since this was a small study, the observations should be regarded as
hypothesis-generating.
Table 4. Mortality rate in the active treatment group compared to the placebo group, and to official mortality statistics.
5.2 years of follow-up 10 years of follow-up
All-cause mort rate Cardiovasc mort rate All-cause mort rate Cardiovasc mort rate
Active group 2433 1130 4427 2079
Placebo group 3115 2423 5400 3870
Reference pop 5794 2144 15,241 6998
Note: Mortality rate expressed as mortality /100,000/year
Note: Reference group: Ofﬁcial Swedish mortality statistics based on the age group 80–84 in the 5.2 year follow-up, and on the age group 85 years and
above in the 10 years follow-up.
doi:10.1371/journal.pone.0141641.t004
Selen and CoenzymeQ10: Reduced Cardiovascular Death after 10 Years
PLOS ONE | DOI:10.1371/journal.pone.0141641 December 1, 2015 13 / 16
Supporting Information
S1 Fig. CONSORT flow chart of the study.
(DOC)
S1 Study Protocol. See Appendix.
(DOCX)
Author Contributions
Conceived and designed the experiments: UA PJ. Performed the experiments: UA. Analyzed
the data: UA JA PJ. Contributed reagents/materials/analysis tools: UA. Wrote the paper: UA
JA PJ.
References
1. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, et al. Selenium in human
health and disease. Antioxid Redox Signal. 2011; 14(7):1337–83. Epub 2010/09/04. doi: 10.1089/ars.
2010.3275 PMID: 20812787.
2. Selenius M, Rundlof AK, Olm E, Fernandes AP, Bjornstedt M. Selenium and the selenoprotein thiore-
doxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid Redox Signal. 2010;
12(7):867–80. Epub 2009/09/23. doi: 10.1089/ars.2009.2884 PMID: 19769465.
3. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and
risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104(22):2673–
8. Epub 2001/11/28. PMID: 11723017.
4. Vassalle C, Bianchi S, Bianchi F, Landi P, Battaglia D, Carpeggiani C. Oxidative stress as a predictor of
cardiovascular events in coronary artery disease patients. Clin Chem Lab Med. 2012; 50(8):1463–8.
Epub 2012/08/08. doi: 10.1515/cclm-2011-0919 PMID: 22868814.
5. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of selenium
supplementation on cardiovascular disease incidence and mortality: secondary analyses in a random-
ized clinical trial. Am J Epidemiol. 2006; 163(8):694–9. Epub 2006/02/24. doi: kwj097 [pii] doi: 10.1093/
aje/kwj097 PMID: 16495471.
6. Venardos KM, Perkins A, Headrick J, Kaye DM. Myocardial ischemia-reperfusion injury, antioxidant
enzyme systems, and selenium: a review. Curr Med Chem. 2007; 14(14):1539–49. Epub 2007/06/23.
PMID: 17584062.
7. Navas-Acien A, Bleys J, Guallar E. Selenium intake and cardiovascular risk: what is new? Curr Opin
Lipidol. 2008; 19(1):43–9. Epub 2008/01/17. doi: 10.1097/MOL.0b013e3282f2b261 PMID: 18196986.
8. Alissa EM, Bahijri SM, Ferns GA. The controversy surrounding selenium and cardiovascular disease: a
review of the evidence. Med Sci Monit. 2003; 9(1):RA9–18. Epub 2003/01/29. PMID: 12552253.
9. RaymanMP. Selenium and human health. Lancet. 2012; 379(9822):1256–68. Epub 2012/03/03. doi:
10.1016/S0140-6736(11)61452-9 PMID: 22381456.
10. U.S. Department of Agriculture ARS. Nutrient Intakes from Food: Mean amounts conusmed per individ-
ual, one day, 2005–2006. Available: www.arsusda.gov/ba/bhnrc/fsrg. Accessed: March 2010. 2008.
11. Rees K, Hartley L, Day C, Flowers N, Clarke A, Stranges S. Selenium supplementation for the primary
prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1:CD009671. Epub 2013/
02/27. doi: 10.1002/14651858.CD009671.pub2 PMID: 23440843.
12. Harris HR, Bergkvist L, Wolk A. Selenium intake and breast cancer mortality in a cohort of Swedish
women. Breast Cancer Res Treat. 2012; 134(3):1269–77. Epub 2012/06/28. doi: 10.1007/s10549-012-
2139-9 PMID: 22736377.
13. Lubos E, Sinning CR, Schnabel RB, Wild PS, Zeller T, Rupprecht HJ, et al. Serum selenium and prog-
nosis in cardiovascular disease: results from the AtheroGene study. Atherosclerosis. 2010; 209
(1):271–7. Epub 2009/10/20. doi: S0021-9150(09)00721-7 [pii] doi: 10.1016/j.atherosclerosis.2009.09.
008 PMID: 19836749.
14. Lauretani F, Semba RD, Bandinelli S, Ray AL, Ruggiero C, Cherubini A, et al. Low plasma selenium
concentrations and mortality among older community-dwelling adults: the InCHIANTI Study. Aging Clin
Exp Res. 2008; 20(2):153–8. PMID: 18431083; PubMed Central PMCID: PMC2746419.
Selen and CoenzymeQ10: Reduced Cardiovascular Death after 10 Years
PLOS ONE | DOI:10.1371/journal.pone.0141641 December 1, 2015 14 / 16
15. Alehagen U, Johansson P, Bjornstedt M, Rosen A, Post C, Aaseth J. Relatively high mortality risk in
elderly Swedish subjects with low selenium status. Eur J Clin Nutr. 2015. doi: 10.1038/ejcn.2015.92
PMID: 26105108.
16. Xia L, Nordman T, Olsson JM, Damdimopoulos A, Bjorkhem-Bergman L, Nalvarte I, et al. The mamma-
lian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for
defense against oxidative stress. J Biol Chem. 2003; 278(4):2141–6. PMID: 12435734.
17. Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Effects of coenzyme Q10 on vascular endothelial func-
tion in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012; 221(2):311–6.
Epub 2011/11/18. doi: 10.1016/j.atherosclerosis.2011.10.027 PMID: 22088605.
18. Bullon P, Roman-Malo L, Marin-Aguilar F, Alvarez-Suarez JM, Giampieri F, Battino M, et al. Lipophilic
antioxidants prevent lipopolysaccharide-induced mitochondrial dysfunction through mitochondrial bio-
genesis improvement. Pharmacol Res. 2015; 91:1–8. doi: 10.1016/j.phrs.2014.10.007 PMID:
25447593.
19. Lee BJ, Tseng YF, Yen CH, Lin PT. Effects of coenzyme Q10 supplementation (300 mg/day) on antiox-
idation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized,
placebo-controlled trial. Nutr J. 2013; 12(1):142. doi: 10.1186/1475-2891-12-142 PMID: 24192015;
PubMed Central PMCID: PMC4176102.
20. Brauner H, Luthje P, Grunler J, Ekberg NR, Dallner G, Brismar K, et al. Markers of innate immune activ-
ity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q10
on inflammatory activity. Clin Exp Immunol. 2014; 177(2):478–82. doi: 10.1111/cei.12316 PMID:
24593795; PubMed Central PMCID: PMC4226598.
21. Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tis-
sues. Lipids. 1989; 24(7):579–84. Epub 1989/07/01. PMID: 2779364.
22. Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U. Cardiovascular mortality and N-termi-
nal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospec-
tive randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol.
2013; 167(5):1860–6. Epub 2012/05/26. doi: 10.1016/j.ijcard.2012.04.156 PMID: 22626835.
23. Jensen-Urstad K, Bouvier F, Hojer J, Ruiz H, Hulting J, Samad B, et al. Comparison of different echo-
cardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during
acute myocardial infarction treated by thrombolytic therapy. Am J Cardiol. 1998; 81(5):538–44. PMID:
9514446.
24. van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and repro-
ducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions.
Am J Cardiol. 1996; 77(10):843–50. PMID: 8623737.
25. Onur S, Niklowitz P, Jacobs G, Lieb W, Menke T, Doring F. Association between serum level of ubiqui-
nol and NT-proBNP, a marker for chronic heart failure, in healthy elderly subjects. Biofactors. 2015; 41
(1):35–43. doi: 10.1002/biof.1198 PMID: 25728634.
26. Bottino DA, Lopes FG, de Oliveira FJ, Mecenas Ade S, Clapauch R, Bouskela E. Relationship between
biomarkers of inflammation, oxidative stress and endothelial/microcirculatory function in successful
aging versus healthy youth: a transversal study. BMCGeriatr. 2015; 15:41. doi: 10.1186/s12877-015-
0044-x PMID: 25888078; PubMed Central PMCID: PMC4393601.
27. Bhayadia R, Schmidt BM, Melk A, HommeM. Senescence-Induced Oxidative Stress Causes Endothe-
lial Dysfunction. J Gerontol A Biol Sci Med Sci. 2015. doi: 10.1093/gerona/glv008 PMID: 25735595.
28. Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, Zeiher AM, et al. Oxidative stress and epigenetic
regulation in ageing and age-related diseases. Int J Mol Sci. 2013; 14(9):17643–63. doi: 10.3390/
ijms140917643 PMID: 23989608; PubMed Central PMCID: PMC3794746.
29. Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly. Biogerontology. 2010; 11(5):635–
41. doi: 10.1007/s10522-010-9292-5 PMID: 20571864.
30. WuD, Meydani SN. Age-associated changes in immune and inflammatory responses: impact of vita-
min E intervention. J Leukoc Biol. 2008; 84(4):900–14. doi: 10.1189/jlb.0108023 PMID: 18596135;
PubMed Central PMCID: PMC2538592.
31. Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age
on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60–
79 years. J Thromb Haemost. 2006; 4(5):982–7. doi: 10.1111/j.1538-7836.2006.01889.x PMID:
16689748.
32. Conti V, Corbi G, Simeon V, Russomanno G, Manzo V, Ferrara N, et al. Aging-related changes in oxi-
dative stress response of human endothelial cells. Aging Clin Exp Res. 2015. doi: 10.1007/s40520-
015-0357-9 PMID: 25835220.
33. Gradinaru D, Borsa C, Ionescu C, Prada GI. Oxidized LDL and NO synthesis-Biomarkers of endothelial
dysfunction and ageing. Mech Ageing Dev. 2015. doi: 10.1016/j.mad.2015.03.003 PMID: 25804383.
Selen and CoenzymeQ10: Reduced Cardiovascular Death after 10 Years
PLOS ONE | DOI:10.1371/journal.pone.0141641 December 1, 2015 15 / 16
34. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, Sim K, et al. Myocardial oxidative stress contributes to
transgenic beta(2)-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol.
2011; 162(5):1012–28. doi: 10.1111/j.1476-5381.2010.01043.x PMID: 20955367; PubMed Central
PMCID: PMC3051376.
35. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardio-
vasc Res. 2009; 81(3):457–64. doi: 10.1093/cvr/cvn335 PMID: 19047340.
36. Littarru GP, Tiano L, Belardinelli R, Watts GF. CoenzymeQ(10), endothelial function, and cardiovascu-
lar disease. Biofactors. 2011; 37(5):366–73. Epub 2011/06/16. doi: 10.1002/biof.154 PMID: 21674640.
37. Alehagen U, Lindahl TL, Aaseth J, Svensson E, Johansson P. Levels of sP-selectin and hs-CRP
Decrease with Dietary Intervention with Selenium and CoenzymeQ10 Combined: A Secondary Analy-
sis of a Randomized Clinical Trial. PLoS One. 2015; 10(9):e0137680. doi: 10.1371/journal.pone.
0137680 PMID: 26375288; PubMed Central PMCID: PMCPMC4574282.
38. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, et al. Establishing optimal selenium
status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2010; 91(4):923–
31. Epub 2010/02/26. doi: 10.3945/ajcn.2009.28169 PMID: 20181815; PubMed Central PMCID:
PMC2844680.
39. Mattmiller SA, Carlson BA, Sordillo LM. Regulation of inflammation by selenium and selenoproteins:
impact on eicosanoid biosynthesis. J Nutr Sci. 2013; 2:e28. doi: 10.1017/jns.2013.17 PMID: 25191577;
PubMed Central PMCID: PMC4153324.
40. Liu H, Li X, Qin F, Huang K. Selenium suppresses oxidative-stress-enhanced vascular smooth muscle
cell calcification by inhibiting the activation of the PI3K/AKT and ERK signaling pathways and endoplas-
mic reticulum stress. J Biol Inorg Chem. 2014; 19(3):375–88. doi: 10.1007/s00775-013-1078-1 PMID:
24390545.
41. Liu H, Lu Q, Huang K. Selenium suppressed hydrogen peroxide-induced vascular smooth muscle cells
calcification through inhibiting oxidative stress and ERK activation. J Cell Biochem. 2010; 111(6):1556–
64. doi: 10.1002/jcb.22887 PMID: 21053344.
42. Helmersson J, Arnlov J, Vessby B, Larsson A, Alfthan G, Basu S. Serum selenium predicts levels of
F2-isoprostanes and prostaglandin F2alpha in a 27 year follow-up study of Swedish men. Free Radic
Res. 2005; 39(7):763–70. doi: 10.1080/10715760500108513 PMID: 16036356.
43. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and
vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention
Trial (SELECT). JAMA. 2009; 301(1):39–51. Epub 2008/12/11. doi: 10.1001/jama.2008.864 PMID:
19066370; PubMed Central PMCID: PMC3682779.
44. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and dis-
ease. Eur J Clin Nutr. 1999; 53(10):764–70. PMID: 10556981.
45. Bonelli L, Puntoni M, Gatteschi B, Massa P, Missale G, Munizzi F, et al. Antioxidant supplement and
long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized trial. J Gas-
troenterol. 2013; 48(6):698–705. doi: 10.1007/s00535-012-0691-z PMID: 23065023.
Selen and CoenzymeQ10: Reduced Cardiovascular Death after 10 Years
PLOS ONE | DOI:10.1371/journal.pone.0141641 December 1, 2015 16 / 16
